ICAAC/IDSA 2008

Contact Us

Forms & Documents
 
Important Dates
 

Abstract Submission Deadline
5/19/08

Pre Meeting Workshops
10/24/08

 
DC Area Resources
 

Metro

Program Information - CPE Credit

Pharmacists
ACPEThe American Society for Microbiology is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. Below is a final detailed list of all sessions and corresponding Universal Program Numbers offering continuing pharmacy education (CPE) credit for participation in select 48th Annual ICAAC/IDSA 46th Annual Meeting sessions. 

Sessions

Session Number

SessionTitle
SED_ACPE
1 Fellows 101
388-999-08-111-L01-P
2 Literature Review 2008
388-999-08-112-L01-P
3 All New Antimicrobial Agents
388-999-08-113-L01-P
48 Plasmid-Mediated Quinolone Resistance
388-999-08-136-L04-P
49 Vaccines in Adolescents and Adults
388-999-08-137-L01-P
50 Clinical Issues with CA-MRSA
388-999-08-138-L01-P
51 Evidence-Based Monitoring for Viral Infections in Transplant Recipients: Who, When, What Specimen, What Assay?
388-999-08-034-L04-P
52 Clinical Controversies in Infectious Diseases
388-999-08-101-L01-P
54 The Role of Microbes in Crohn's Disease
388-999-08-037-L04-P
55 What is New in Beta-Lactamase Detection, Epidemiology, Control and Clinical Impact?
388-999-08-131-L01-P
56 New Molecules from Old Classes: Is There Still Room for Improvement?
388-999-08-046-L01-P
57 Vaccination in Early Life: Problems and Possibilities
388-999-08-022-L01-P
58 HIV and the Global Pandemic
388-999-08-133-L02-P
59 Health and Economic Impact of Multiple-Drug Resistant Organism Screening
388-999-08-057-L01-P
60 UTIs in Special Populations
388-999-08-033-L01-P
61 Immunotherapy for Medical Mycoses
388-999-08-021-L01-P
62 Emerging Viral and Bacterial Issues in Asia-Pacific Regions
388-999-08-139-L04-P
63 Opening Keynote Session
388-999-08-135-L01-P
64 Tolerance and Rate of Kill: Obverse Sides of the Coin - Importance to Clinical Outcomes
388-999-08-141-L04-P
65 What do ID Physicians Really Think about the Clinical Microbiology Lab?
388-999-08-043-L04-P
66 Latest Advisory Committee on Immunization Practices (ACIP) and Red Book Committee Recommendations
388-999-08-065-L03-P
67 HIV Pharmacology
388-999-08-142-L02-P
68 Pediatric HIV
388-999-08-097-L02-P
69 Practical Issues with Pandemic Flu Preparedness at the Institutional Level
388-999-08-094-L01-P
69a Difficult Cases in Clinical Mycology
388-999-08-121-L01-P
70 New Challenges in the Diagnosis, Management and Prevention of Central Venous Catheter-Related Infections
388-999-08-092-L01-P
71 Hepatitis C Management
388-999-08-102-L01-P
71a Top Ten Papers in Clinical Mycology
388-999-08-119-L01-P
72 Toxicodynamics
388-999-08-124-L01-P
73 Pathogenesis of CNS Infections
388-999-08-024-L01-P
74 New Concepts on the Bacterial Cell Wall
388-999-08-109-L01-P
75 Immunization of Adolescents and Adults
388-999-08-045-L01-P
76 New Developments in Orthopaedic Infections
388-999-08-072-L01-P
77 Emerging Issues in Tropical Medicine
388-999-08-089-L01-P
78 Mycobacteria: New Therapies, Mechanisms and Models
388-999-08-129-L01-P
79 Beta-Lactamase: Structure and Function
388-999-08-143-L04-P
80 Antiretroviral Therapy
388-999-08-144-L02-P
81 Outbreaks and Pseudo-Outbreaks
388-999-08-145-L01-P
82 New Issues with Community-Acquired Pneumonia
388-999-08-146-L01-P
83 Influenza
388-999-08-147-L01-P
84 Challenging Cases in Pediatric Infectious Diseases
388-999-08-095-L01-P
85 Clinical Challenges in Managing Osteomyelitis: Tough Questions Your Students May Ask You
388-999-08-079-L01-P
86 Laboratory Diagnosis of HPV in the Vaccine Era
388-999-08-074-L01-P
87 The Role of Medicinal Chemistry in Antimicrobial Drug Discovery
388-999-08-051-L04-P
88 HIV Genomics: Bench to Bedside
388-999-08-148-L02-P
89 Evidence-Based Practices in Infection Control
388-999-08-062-L01-P
90 New Endocarditis Prophylaxis Guidelines
388-999-08-149-L01-P
137 Colistin Pharmacokinetics/Dynamics
388-999-08-150-L04-P
138 Basic Mechanisms of Bacterial Toxin Action
388-999-08-151-L04-P
139 Continuing Persistance of CTX-M ESBLs in Clinical Isolates
388-999-08-152-L04-P
140 Pediatric Infectious Diseases
388-999-08-153-L01-P
141 MRSA Screening and Decolonization: Does it Work and is it Cost-Effective?
388-999-08-154-L01-P
142 From the Clinical Mycology Laboratory
388-999-08-155-L04-P
143 Best Practices in the Laboratory Diagnosis of Respiratory Tract Infections
388-999-08-061-L01-P
144 Antimicrobial Tolerance: Persisters, Biofilms, and Infectious Diseases
388-999-08-049-L01-P
145 What is the Best Way to Study the Relationship between Antibiotic Use and Resistance?
388-999-08-156-L01-P
146 New Approaches Circumventing Classical Drug Targets
388-999-08-047-L01-P
147 State-of-the-Art in HIV Care and Treatment
388-999-08-040-L02-P
148 CMS and the Practice of Infectious Diseases
388-999-08-060-L03-P
149 Vaccines for Global Health
388-999-08-090-L01-P
150 CMV: Not Only in Transplants
388-999-08-106-L01-P
151b Omics for Idiots
388-999-08-114-L01-P
152 Bacterial Identification by DNA Sequencing
388-999-08-055-L04-P
153 How to Fund a Pediatric Infectious Diseases Section
388-999-08-023-L03-P
154 HIV and Pregnancy
388-999-08-118-L02-P
155 HIV Drug Resistance Testing
388-999-08-071-L02-P
155a Vaccine Preventable Diseases for Healthcare Workers
388-999-08-122-L04-P
156 Preventing Healthcare-Associated Infection in the ICU: What's Next?
388-999-08-093-L01-P
157 CMV in Transplantation
388-999-08-042-L01-P
158 Pharmacokinetics/Pharmacodynamics and Formulary Committees
388-999-08-066-L01-P
159 Endocarditis
388-999-08-157-L01-P
160 Genomics: What do We Expect and What Did We Get?
388-999-08-158-L04-P
161 Management of CNS Infections: Resistant Pathogens and Devices
388-999-08-078-L01-P
162 Adolescent HIV
388-999-08-039-L02-P
163 Patient Empowerment as a Hand Hygiene Promotion Strategy
388-999-08-053-L05-P
163a New CDC Guidelines on Isolation Precautions
388-999-08-180-L04-P
164 Problem Infestations: Scabies and Lice
388-999-08-031-L01-P
165 The Clinical Role of Probiotics
388-999-08-027-L01-P
166 Tricks with TRAPS
388-999-08-082-L01-P
167 Varicella-Zoster Virus Vaccination
388-999-08-110-L01-P
168 Challenges in Hepatitis B Management
388-999-08-103-L01-P
168a Decreasing the Risk of Antibacterial Drug Development through Pharmacokinetics/Pharmacodynamics
388-999-08-134-L04-P
169 Bacterial Colonization of the Human Host
388-999-08-044-L04-P
170 Communicating Infectious Diseases and Vaccine Issues to the Public
388-999-08-104-L01-P
171 What's Hot in ID and HIV?
388-999-08-028-L02-P
172 Controversies in the Clinical Management of Severe Sepsis
388-999-08-081-L01-P
173 Improving Management of STIs
388-999-08-035-L01-P
174 Is Anything Better than Vancomycin? What Every Clinician Should Know about the Newer Anti Gram-Positives
388-999-08-159-L01-P
175 Update in Antiparasitic Therapy
388-999-08-091-L01-P
176 Pharmacodynamic Studies of Unique Bacterial Pathogens
388-999-08-160-L04-P
177 MRSA and Other Resistant Bacteria in Animals and Man
388-999-08-161-L01-P
178 Sequence-Based Typing of Streptococcus pneumoniae
388-999-08-162-L01-P
179 Clinical Mycology
388-999-08-163-L01-P
180 New and Old Viruses
388-999-08-164-L01-P
181 Animals, Humans and Public Health
388-999-08-063-L01-P
181a Difficult Mycology Questions for the ID Consultant
388-999-08-116-L01-P
181b Global Perspective on Antibiotic Stewardship
388-999-08-132-L04-P
182 Staphylococcus epidermidis Infections
388-999-08-029-L01-P
183 HIV and Women
388-999-08-048-L02-P
184 New Issues with Tick-Borne Diseases
388-999-08-165-L01-P
225 Human Pharmacodynamics of Effect and Toxicity
388-999-08-166-L01-P
226 S. aureus Virulence and Gene Expression
388-999-08-167-L01-P
228 Emerging Issues in Gastrointestinal Infections
388-999-08-168-L01-P
229 Malaria
388-999-08-169-L01-P
230 Pharmacodynamic and Pharmacokinetic Approaches to Enhancing Existing Therapies for Gram-Negative Infection
388-999-08-067-L01-P
231 Current Issues and Controversies in HIV Infection Management
388-999-08-073-L02-P
232 Infectious Complications of Targeted Immunotherapies
388-999-08-098-L01-P
233 Drug Addiction in Bacteria
388-999-08-075-L01-P
234 Invasive Aspergillosis: New Diagnostic Platforms and Targets
388-999-08-036-L04-P
235 Novel Approaches in Biofilms
388-999-08-038-L01-P
236 Hot Topics in Pediatric Infectious Diseases
388-999-08-100-L01-P
237 Clostridium difficile: Have We Reached Bottom Yet?
388-999-08-076-L01-P
238 Emerging and Reemerging Infections
388-999-08-084-L01-P
239 Tropical Viral Infections
388-999-08-108-L01-P
241a Bone and Joint Infections
388-999-08-123-L01-P
242 Top Ten Papers in Beta-Lactamases
388-999-08-115-L01-P
243 How Predictive are our Preclinical Safety Models?
388-999-08-050-L01-P
244 2007-2008 Top Ten Papers in Hospital Epidemiology and Infection Control
388-999-08-052-L01-P
245 Infection Control in Developing Countries
388-999-08-056-L01-P
246 Endemic Mycoses
388-999-08-086-L01-P
247 Update on Travel Medicine
388-999-08-099-L01-P
248 Serine Carbapenemases
388-999-08-170-L01-P
249 MRSA Screening: Impact of Governmental Mandates
388-999-08-058-L04-P
250 Prevention and Treatment of Rabies: Before and After the Bite
388-999-08-064-L01-P
251 Training/Working in International Settings
388-999-08-069-L03-P
251b Surgical Site Infection Prevention Strategies
388-999-08-120-L01-P
252 Fungal Infections in Transplant Recipients
388-999-08-087-L01-P
252a Friday Afternoon with the Hospital Epidemiologist Beeper
388-999-08-117-L04-P
253 Update on the Antifungal Formulary
388-999-08-020-L01-P
254 2008 Susceptibility Testing Update
388-999-08-054-L01-P
255 Challenges and New Approaches in Mycobacterial Infections
388-999-08-068-L01-P
256 Advances in HIV Pathogenesis
388-999-08-070-L02-P
257 Meningoencephalitis in Special Populations
388-999-08-080-L01-P
258 Update on Cryptococcosis
388-999-08-085-L01-P
259 Emerging and Reemerging Viruses
388-999-08-059-L01-P
260 Immune Response to Infections In Vivo
388-999-08-128-L01-P
261 New Drugs versus Staphylococcus aureus and Staphylococcus epidermidis
388-999-08-171-L01-P
262 Resistance Mechanisms of Acinetobacter and Pseudomonas
388-999-08-172-L01-P
263 KPC β-Lactamase Continues to Go Global
388-999-08-179-L04-P
264 Pediatric Vaccines
388-999-08-173-L01-P
265 Breaking Your Heart with Infection
388-999-08-127-L01-P
266 Experimental Mycology
388-999-08-174-L01-P
267 Herpes Viruses and Transplantation Viral Infections
388-999-08-175-L01-P
268 Challenging Cases in Tropical Medicine
388-999-08-088-L01-P
269 Get the Zinc Out: Metallo-Beta-Lactamases
388-999-08-041-L01-P
270 Update on Community-Associated Methicillin-Resistant Staphylococcus aureus
388-999-08-030-L01-P
271 Vexing Viruses in Children and Adolescents
388-999-08-105-L01-P
272 Infections in Long-Term Care: What All ID Clinicians Must Know
388-999-08-077-L01-P
273 Transplant Viral Infections
388-999-08-107-L01-P
304 Immunobiology of Respiratory Infections
388-999-08-130-L01-P
305 Old and New Glyco- and Glyco-Lipo Peptides
388-999-08-126-L01-P
307 Epidemiology and Treatment of C. difficile
388-999-08-125-L01-P
308 Seasonal and Pandemic Influenza
388-999-08-176-L01-P
309 Respiratory Viruses and Hepatitis
388-999-08-177-L01-P
310 Combination Therapy for MRSA Infection
388-999-08-026-L01-P
311 HIV, STDs and the Global AIDS Pandemic: Lethal Synergy 2008
388-999-08-032-L02-P
312 Seasonal Influenza: Controversies in How to Protect the Population
388-999-08-083-L01-P
313 Complex Medical Management of HIV
388-999-08-096-L02-P
314 Clinical Management of Community-Acquired Pneumonia (CAP)
388-999-08-178-L01-P
315 Environmental Moulds and Human Disease: Is There a Connection?
388-999-08-025-L04-P

 

Workshops

Session Number Session Title UPN
48-01 Vincent T. Andriole ID Review Course 388-999-08-001-L01-P
48-02 Pediatric Infectious Disease Society Fellows' Day 2008 388-999-08-002-L01-P
48-03 Expansion of HIV Testing and Implications for STD Management 388-999-08-003-L02-P
48-04 What's New in TB in 2008 388-999-08-004-L01-P
48-05 Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents (half-day) 388-999-08-005-L01-P
48-06 Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents (half-day) 388-999-08-006-L01-P
48-07 PK/PD Modeling of Anti-Infective Agents (half-day) 388-999-08-007-L01-P
48-08 PK/PD Full-Day Workshop Combining 48-05 and 48-06 388-999-08-008-L01-P
48-09 PK/PD Full-Day Workshop Combining 48-05 and 48-07 388-999-08-009-L01-P
48-10 Clinical Mycology: Practical Information for the Clinician 388-999-08-010-L01-P
48-11 Monitoring, Evaluating and Managing Antimicrobial Use in Hospitals 388-999-08-011-L01-P
48-12 Optimizing Screening of Organs for Transplantation: New Technologies and Future Directions 388-999-08-012-L01-P
48-14 Antibiotic Resistance among Bacterial Pathogens: Mechanisms, Detection, and Molecular Epidemiology 388-999-08-013-L01-P

Statements of Credit will indicate credits based on participation.  ASM complies with the ACPE Criteria for Quality and Interpretive Guidelines.